veliflapon
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2006 (NCT00353067)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- 5-lipoxygenase activating proteinINHIBITOR
ALOX5AP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)[C@@H](c1ccc(OCc2ccc3ccccc3n2)cc1)C1CCCC1- Mol. weight
- 361.44 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL88712 ↗
Also known as
- 2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid
- bay-x-005
- bay-x-005
- bay x1005
- bay x 1005
- bay-x1005
- bay-x-1005
- bay-x-1005
- bayx-1005
- benzeneacetic acid, alpha-cyclopentyl-4-(2-quinolinylmethoxy)-, (r)-
- dg-031
- dg-031
- dg-031
- veliflapon
- veliflapon
- veliflapon
- veliflapon
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00353067 | Phase 3 | May 1, 2006 | deCODE genetics, Duke University, Henry Ford Health System |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| deCODE genetics | For profit | 1 | 1 | 1 | 2006 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2006 |
3 organizations
Page 1 / 1